Cell-Free Tissue Engineered Vascular Grafts

Researchers at Nationwide Children’s Hospital have developed a novel method for increasing the patency of biodegradable, synthetic vascular grafts. Administration or controlled release of one or more cytokines or chemokines was found to promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. As a result, this method does not require cell seeding of the vascular graft, eliminating many problems associated with cell seeding such as contamination, loss of clinical utility due to added time for cell expansion, and difficulty in obtaining healthy autologous cells from diseased donors.

Patents

Patent # Title Country
9,326,951 Cell-Free Tissue Engineered Vascular Grafts United States of America
10,300,082 Cell-Free Tissue Engineered Vascular Grafts United States of America

Loading icon